Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
tumor
Biotech
Hummingbird uses VISTA buzz to secure $290M pact for tumor drug
Hummingbird could one day feather its nest with up to $290 million if its decision to license a phase 2-ready cancer drug to Percheron pays off.
James Waldron
Jun 26, 2025 4:53am
Mosaic licenses 2 clinical stage tumor drugs from Otsuka's Astex
Apr 24, 2025 10:00am
Merck KGaA pays $85M for global rights to Abbisko's tumor drug
Apr 1, 2025 7:40am
Takeda's oncology execs sharpen focus after restructuring
Mar 13, 2025 10:59am
Merck KGaA tacks on Abbisko’s joint tumor med for $70M upfront
Dec 4, 2023 10:26am
Deciphera's tumor-tackling oral med achieves 40% response rate
Oct 30, 2023 11:00am